{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04281498","nct_id":"NCT04281498","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04281498. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Ruxolitinib and Enasidenib combination therapy","label":"Patients with MPN","type":"EXPERIMENTAL"}],"collaborators":["Celgene Corporation","Incyte Corporation","Myeloproliferative Neoplasms Research Consortium","National Institutes of Health (NIH)","National Cancer Institute (NCI)"],"completion_date":{"date":"2023-05-30","type":"ACTUAL"},"conditions":["Accelerated/Blast-phase Myeloproliferative Neoplasm","Chronic-phase Myelofibrosis","IDH2 Mutation"],"enrollment":{"count":6,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Ruxolitinib","otherNames":[],"type":"DRUG"},{"name":"Enasidenib","otherNames":[],"type":"DRUG"}],"last_update":"2025-02-04","lead_sponsor":"John Mascarenhas","official_title":"A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-05-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of MPN Participants With Response","timeFrame":"6 Months"}],"references":[],"start_date":{"date":"2021-01-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","url":"https://clinicaltrials.gov/study/NCT04281498"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04281498"}